TY - JOUR T1 - In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. AU - Pizzorno,Andrés, AU - Padey,Blandine, AU - Dubois,Julia, AU - Julien,Thomas, AU - Traversier,Aurélien, AU - Dulière,Victoria, AU - Brun,Pauline, AU - Lina,Bruno, AU - Rosa-Calatrava,Manuel, AU - Terrier,Olivier, Y1 - 2020/07/15/ PY - 2020/05/06/received PY - 2020/07/06/revised PY - 2020/07/07/accepted PY - 2020/7/18/pubmed PY - 2020/9/8/medline PY - 2020/7/18/entrez KW - Antivirals KW - Berberine KW - COVID-19 KW - Diltiazem KW - Drug combination KW - Remdesivir SP - 104878 EP - 104878 JF - Antiviral research JO - Antiviral Res VL - 181 N2 - In response to the current pandemic caused by the novel SARS-CoV-2, identifying and validating effective therapeutic strategies is more than ever necessary. We evaluated the in vitro antiviral activities of a shortlist of compounds, known for their cellular broad-spectrum activities, together with drugs that are currently under evaluation in clinical trials for COVID-19 patients. We report the antiviral effect of remdesivir, lopinavir, chloroquine, umifenovir, berberine and cyclosporine A in Vero E6 cells model of SARS-CoV-2 infection, with estimated 50% inhibitory concentrations of 0.99, 5.2, 1.38, 3.5, 10.6 and 3 μM, respectively. Virus-directed plus host-directed drug combinations were also investigated. We report a strong antagonism between remdesivir and berberine, in contrast with remdesivir/diltiazem, for which we describe high levels of synergy, with mean Loewe synergy scores of 12 and peak values above 50. Combination of host-directed drugs with direct acting antivirals underscore further validation in more physiological models, yet they open up interesting avenues for the treatment of COVID-19. SN - 1872-9096 UR - https://www.unboundmedicine.com/medline/citation/32679055/In_vitro_evaluation_of_antiviral_activity_of_single_and_combined_repurposable_drugs_against_SARS_CoV_2_ DB - PRIME DP - Unbound Medicine ER -